Daiichi Sankyo Company, Limited (TYO:4568)

Market Cap	5.11T -22.3%
Revenue (ttm)	2.22T +15.5%
Net Income	243.01B -17.9%
EPS	131.93 -16.0%
Shares Out	1.82B
PE Ratio	21.26
Forward PE	19.35
Dividend	100.00 (3.57%)
Ex-Dividend Date	Sep 29, 2026

Volume	5,466,300
Open	2,714.50
Previous Close	2,805.00
Day's Range	2,713.50 - 2,805.00
52-Week Range	2,390.00 - 4,178.00
Beta	-0.18
Analysts	Buy
Price Target	4,078.82 (+45.41%)
Earnings Date	Jul 31, 2026

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injec...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1899
• Employees: 20,171
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4568

Financial Performance

In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 259.87 billion, a decrease of -12.13%.

Analyst Summary

According to 17 analysts, the average rating for 4568 stock is "Buy." The 12-month stock price target is ¥4,079, which is an increase of 45.41% from the latest price.

Price Target

¥4,079

(45.41% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error